JP2016533749A5 - - Google Patents

Download PDF

Info

Publication number
JP2016533749A5
JP2016533749A5 JP2016537333A JP2016537333A JP2016533749A5 JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5 JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016537333 A JP2016537333 A JP 2016537333A JP 2016533749 A5 JP2016533749 A5 JP 2016533749A5
Authority
JP
Japan
Prior art keywords
newcastle disease
disease virus
attenuated newcastle
virus
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016537333A
Other languages
English (en)
Japanese (ja)
Other versions
JP6557234B2 (ja
JP2016533749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/068619 external-priority patent/WO2015032755A1/en
Publication of JP2016533749A publication Critical patent/JP2016533749A/ja
Publication of JP2016533749A5 publication Critical patent/JP2016533749A5/ja
Application granted granted Critical
Publication of JP6557234B2 publication Critical patent/JP6557234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016537333A 2013-09-03 2014-09-02 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法 Expired - Fee Related JP6557234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03
US61/873,039 2013-09-03
PCT/EP2014/068619 WO2015032755A1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019129161A Division JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Publications (3)

Publication Number Publication Date
JP2016533749A JP2016533749A (ja) 2016-11-04
JP2016533749A5 true JP2016533749A5 (https=) 2017-10-12
JP6557234B2 JP6557234B2 (ja) 2019-08-07

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537333A Expired - Fee Related JP6557234B2 (ja) 2013-09-03 2014-09-02 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法
JP2019129161A Expired - Fee Related JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019129161A Expired - Fee Related JP6862500B2 (ja) 2013-09-03 2019-07-11 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法

Country Status (25)

Country Link
US (2) US10519426B2 (https=)
EP (3) EP3041490B1 (https=)
JP (2) JP6557234B2 (https=)
KR (2) KR102285894B1 (https=)
CN (2) CN111944767A (https=)
AU (2) AU2014317215C1 (https=)
CA (1) CA2922071C (https=)
CY (2) CY1121993T1 (https=)
DK (2) DK3041490T3 (https=)
EA (2) EA202191926A3 (https=)
ES (2) ES2914577T3 (https=)
HK (1) HK1231393A1 (https=)
HR (2) HRP20220653T1 (https=)
HU (1) HUE042382T2 (https=)
LT (2) LT3508209T (https=)
ME (1) ME03345B (https=)
MX (2) MX367768B (https=)
PL (2) PL3508209T3 (https=)
PT (2) PT3508209T (https=)
RS (2) RS63291B1 (https=)
SI (2) SI3041490T1 (https=)
SM (2) SMT201900094T1 (https=)
TR (1) TR201902073T4 (https=)
TW (1) TWI653334B (https=)
WO (1) WO2015032755A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) * 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
CN107847610B (zh) * 2015-04-28 2022-02-01 塞维卡有限责任公司 基于piv5的扩增病毒样颗粒
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
EP3246410A1 (en) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
CN112739359A (zh) * 2018-07-13 2021-04-30 西奈山伊坎医学院 Apmv及其用于治疗癌症的用途
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状rna組成物及び方法
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
US20220396809A1 (en) * 2021-06-03 2022-12-15 University Of Guelph Engineered newcastle disease virus vector and uses thereof
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体:制造方法和用途
WO2025116613A1 (ko) * 2023-11-29 2025-06-05 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
ATE451835T1 (de) * 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (en) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2968525A4 (en) * 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) * 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Similar Documents

Publication Publication Date Title
JP2016533749A5 (https=)
JP2019193662A5 (https=)
Zamarin et al. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
Janke et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
US11471499B2 (en) Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
Collins et al. Viral vectors in cancer immunotherapy: which vector for which strategy?
Asad et al. Viral gene therapy for breast cancer: progress and challenges
BR112019020001A2 (pt) linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
HRP20231025T1 (hr) Onkolitički virus vakcinije
JP2014207903A5 (https=)
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
JP2013151523A (ja) Rnaウイルスが導入された樹状細胞を含む抗癌剤
JP2016503029A5 (https=)
CN118436692A (zh) 表达il12的溶瘤弹状病毒
JP2019508403A5 (https=)
JP2016513115A5 (https=)
Zhao et al. Newcastle disease virus: a promising agent for tumour immunotherapy
JP2019533015A5 (https=)
JP2021530501A5 (https=)
JP2015506179A5 (https=)
Bin Liu et al. Virus, oncolytic virus and human prostate cancer
JP2017522326A5 (https=)
JP2018522880A5 (https=)
Sokke Umeshappa et al. CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination
Lapp et al. Viral oncolysis—can insights from measles be transferred to canine distemper virus?